|
|||||
|
|
||||||
Originally published as JCO Early Release 10.1200/JCO.2005.03.9073 on December 27 2005 © 2006 American Society of Clinical Oncology. Outcome of Critically Ill Allogeneic Hematopoietic Stem-Cell Transplantation Recipients: A Reappraisal of Indications for Organ Failure SupportsFrom the Medical Intensive Care Unit, Cochin Hospital, AP-HP; Medical Intensive Care Unit and Bone Marrow Transplantation Unit, Saint-Louis Hospital, AP-HP; Hematology Department, Necker Hospital, AP-HP; Faculty of Medicine, Paris V-René Descartes University; Faculty of Medicine, Paris VII-Denis Diderot University, Paris; and Intensive Care Unit and Bone Marrow Transplantation Unit, Institut Gustave Roussy, Villejuif, France Address reprint requests to Frédéric Pène, MD, Service de Réanimation Médicale, Hôpital Cochin, 27 rue du Faubourg Saint-Jacques, 75014 Paris, France; e-mail: frederic.pene{at}cch.aphp.fr PURPOSE: Because the overall outcome of critically ill hematologic patients has improved, we evaluated the short-term and long-term outcomes of the poor risk subgroup of allogeneic hematopoietic stem-cell transplantation (HSCT) recipients requiring admission to the intensive care unit (ICU). PATIENTS AND METHODS: This was a retrospective multicenter study of allogeneic HSCT recipients admitted to the ICU between 1997 and 2003.
RESULTS: Two hundred nine critically ill allogeneic HSCT recipients were included in the study. Admission in the ICU occurred during the engraftment period ( CONCLUSION: Extensive unlimited intensive care support is justified for allogeneic HSCT recipients with complications occurring during the engraftment period. Conversely, initiation or maintenance of mechanical ventilation is questionable in the setting of active GVHD. F.P. and C.A. contributed equally to this work and should both be considered as first authors. Presented in part at the 46th Annual Meeting of the American Society of Hematology, San Diego, CA, December 4-7, 2004. Authors' disclosures of potential conflicts of interest and author contributions are found at the end of this article.
This article has been cited by other articles:
|
||||||||||||||||||||||||
|
|||||||||||
|
Copyright © 2006 by the American Society of Clinical Oncology, Online ISSN: 1527-7755. Print ISSN: 0732-183X
|